Study S001371

Effects of EXEnatide on Glycemic Control and Weight Over 26 Weeks in Continuous Subcutaneous Insulin Infusion (CSII) Treated Patients With Type 2 Diabetes : a Phase 2/3 Double Blind randoMized Placebo-controlled Trial.

ClinicalTrials.gov record

Registration

Registration: NCT01140893
Acronym: EXEPUMP
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2; PHASE3
Masking: QUADRUPLE
Status: UNKNOWN
Enrollment: 110
Start: 2010-11
Primary completion: 2017-05
Lead sponsor: University Hospital, Caen
Conditions: Type 2 Diabetes
Interventions: DRUG:Exenatide; DRUG:Placebo
Results posted: FALSE

Registered primary outcomes

Change from baseline to 6 months of centrally measured HbA1c [baseline to 6 months]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.